Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATShares IssuedShares Outstanding
Ratios

Lipocine (LPCN) Non-Current Receivables (2021 - 2023)

Historic Non-Current Receivables for Lipocine (LPCN) over the last 3 years, with Q2 2023 value amounting to $3.3 million.

  • Lipocine's Non-Current Receivables fell 1969.14% to $3.3 million in Q2 2023 from the same period last year, while for Jun 2023 it was $3.3 million, marking a year-over-year decrease of 1969.14%. This contributed to the annual value of $3.3 million for FY2022, which is 1969.14% down from last year.
  • According to the latest figures from Q2 2023, Lipocine's Non-Current Receivables is $3.3 million, which was down 1969.14% from $3.3 million recorded in Q1 2023.
  • Over the past 5 years, Lipocine's Non-Current Receivables peaked at $4.0 million during Q4 2021, and registered a low of $3.3 million during Q3 2022.
  • Over the past 3 years, Lipocine's median Non-Current Receivables value was $3.3 million (recorded in 2022), while the average stood at $3.6 million.
  • Over the last 5 years, Lipocine's Non-Current Receivables had its largest YoY gain of 1969.14% in 2022, and its largest YoY loss of 1969.14% in 2022.
  • Over the past 3 years, Lipocine's Non-Current Receivables (Quarter) stood at $4.0 million in 2021, then dropped by 19.69% to $3.3 million in 2022, then changed by 0.0% to $3.3 million in 2023.
  • Its Non-Current Receivables was $3.3 million in Q2 2023, compared to $3.3 million in Q1 2023 and $3.3 million in Q4 2022.